AI assistant
Sending…
Amphastar Pharmaceuticals, Inc. — Director's Dealing 2018
Mar 16, 2018
10216_dirs_2018-03-16_dc4aa542-6bd5-4b3f-bb22-88307f089c11.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Amphastar Pharmaceuticals, Inc. (AMPH)
CIK: 0001297184
Period of Report: 2018-03-15
Reporting Person: PRINS RICHARD K (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-03-15 | Common Stock | M | 16598 | $14.66 | Acquired | 45442 | Direct |
| 2018-03-15 | Common Stock | S | 16598 | $19.9011 | Disposed | 28844 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-03-15 | Stock Option (right to buy) | $14.66 | M | 16598 | Disposed | 2018-12-20 | Common Stock (16598) | Direct |
Footnotes
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.77 to $20.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
F2: Shares subject to the option are fully vested and immediately exercisable.
More from Amphastar Pharmaceuticals, Inc.
Investor Presentation
2026
May 14
Interim / Quarterly Report
2026
May 7
Investor Presentation
2026
May 7
Investor Presentation
2026
Apr 14
Annual Report
2026
Apr 13
Proxy Solicitation & Information Statement
2026
Apr 13
Director's Dealing
2026
Mar 18
Director's Dealing
2026
Mar 17
Director's Dealing
2026
Mar 17
Director's Dealing
2026
Mar 17